In last trading session, Aquestive Therapeutics Inc (NASDAQ:AQST) saw 2.08 million shares changing hands with its beta currently measuring 2.94. Company’s recent per share price level of $3.37 trading at $0.01 or 0.15% at ring of the bell on the day assigns it a market valuation of $302.75M. That closing price of AQST’s stock is at a discount of -84.87% from its 52-week high price of $6.23 and is indicating a premium of 62.91% from its 52-week low price of $1.25. Taking a look at company’s average trading volume volume of 2.75 million if we extend that period to 3-months.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Upright in the green during last session for gaining 0.15%, in the last five days AQST remained trading in the red while hitting it’s week-highest on Friday, 04/26/24 when the stock touched $3.37 price level, adding 20.71% to its value on the day. Aquestive Therapeutics Inc’s shares saw a change of 66.58% in year-to-date performance and have moved -13.72% in past 5-day. Aquestive Therapeutics Inc (NASDAQ:AQST) showed a performance of -18.72% in past 30-days.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Statistics highlight that Aquestive Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 122.85% of value to its shares in past 6 months, showing an annual growth rate of -176.92% while that of industry is 11.40. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -172.70% in the current quarter and calculating 10.00% increase in the next quarter. This year revenue growth is estimated to rise 14.60% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $12.26 million for the same. And 8 analysts are in estimates of company making revenue of $12.6 million in the next quarter that will end on Jun 2024. Company posted $11.13 million and $13.24 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 10.10% while estimating it to be -4.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 46.61% during past 5 years.
AQST Dividends
Aquestive Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
